Other Significant Balance Sheet Accounts

9 Months Ended

Sep. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Other Significant Balance Sheet Accounts

Note 6. Other Significant Balance Sheet Accounts

Other current assets consisted of the following:

	September 30,		December 31,
	2021		2020
	(in thousands)
Reagents and supplies	$	21,950	$	16,491
Prepaid expenses		5,348		3,682
Marketable securities interest receivable		2,724		1,016
Other receivable		1,807		17,810
Contract assets		206		1,379
Prepaid income taxes		—		14
Total	$	32,035	$	40,392

Reagents and supplies include reagents and consumables used for COVID-19 testing and genetics testing and collection kits for COVID-19 testing. Other receivable as of December 31, 2020 primarily consists of proceeds to be received from public offerings of the Company’s common stock, which were all collected during the nine months ended September 30, 2021.

Other current liabilities consisted of the following:

	September 30,		December 31,
	2021		2020
	(in thousands)
Payable to a broker	$	20,092	$	—
Contingent consideration		8,500		—
Payroll liabilities		8,380		5,314
Operating lease liabilities, short term		1,830		267
Due to related parties		634		409
Sales tax payable and other		467		2,538
Finance lease liabilities, short term		16		—
Total	$	39,919	$	8,528

The payable to a broker of $20.1 million was for marketable securities purchased before the period-end that did not settle until after period-end, and contingent consideration of $8.5 million was related to the acquisition of CSI (see Note 14).